ArticleCureus2025
C-reactive Protein Trends and Clinical Outcomes in Patients Treated for Complicated Parapneumonic Effusion and Empyema.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment endpoints of empyema thoracis lack specificity when determining clinical success. While a declining C-reactive protein (CRP) may indicate a response to treatment, the expected rate of decline is not well-established. An observational analysis was performed on patients who were treated for either a parapneumonic effusion or empyema by tube thoracostomy and possessed at least two sequential CRP measurements. CRP trends were retrospectively modeled in a cohort of 104 patients. The rate of CRP decline was affected by the use of intrapleural enzymatic therapy, baseline CRP, and the value of the pleural pH. CRP declined at a daily rate of 12.3% in those who received intrapleural enzymatic therapy (IET) and by 17.8% in those who did not, but frequently remains elevated at discharge, thus lacking specificity as an isolated biomarker in determining treatment success or failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.